Cargando…

High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma

High-dose ipilimumab (IPI) and high-dose interleukin-2 (IL-2) are approved agents for metastatic melanoma, but the efficacy and safety of the combination are unknown. The objective of this study was to evaluate the feasibility, safety, and efficacy of combination high-dose IPI and high-dose IL-2 in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Silk, Ann W., Kaufman, Howard L., Curti, Brendan, Mehnert, Janice M., Margolin, Kim, McDermott, David, Clark, Joseph, Newman, Jenna, Bommareddy, Praveen K., Denzin, Lisa, Najmi, Saltanat, Haider, Azra, Shih, Weichung, Kane, Michael P., Zloza, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965158/ https://www.ncbi.nlm.nih.gov/pubmed/31998643 http://dx.doi.org/10.3389/fonc.2019.01483

Ejemplares similares

A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma
por: Silk, Ann W., et al.
Publicado: (2023)

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
por: Buchbinder, Elizabeth I., et al.
Publicado: (2016)

Efficacy and safety of high-dose interleukin-2 treatment in patients with a history of brain metastases from renal cell carcinoma
por: Chandar, Ashwin, et al.
Publicado: (2015)

A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors
por: Silk, Ann W., et al.
Publicado: (2022)

Response to high dose ipilimumab plus temozolomide after progression on standard or low dose ipilimumab in advanced melanoma: a retrospective analysis
por: Williamson, Julie, et al.
Publicado: (2023)

Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma
por: Bommareddy, Praveen K., et al.
Publicado: (2019)

Cost‐effectiveness of ipilimumab versus high‐dose interferon as an adjuvant therapy in resected high‐risk melanoma
por: Salans, Mia, et al.
Publicado: (2021)

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
por: Chesney, Jason, et al.
Publicado: (2019)

High dose interleukin-2 registry, PROCLAIM™; higher center-specific IL-2 dose density correlates with higher response rates
por: Wong, Michael K, et al.
Publicado: (2013)

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
por: Buchbinder, Elizabeth I., et al.
Publicado: (2019)

Oncolytic Viruses—Natural and Genetically Engineered Cancer Immunotherapies
por: Jhawar, Sachin R., et al.
Publicado: (2017)

Role of dose selection in successful interleukin-2 immunotherapy: solving the Goldilock’s Complex
por: Zloza, Andrew, et al.
Publicado: (2013)

Ipilimumab in a Phase II trial of melanoma patients with brain metastases
por: Margolin, Kim
Publicado: (2012)

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
por: Alva, Ajjai, et al.
Publicado: (2016)

Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2
por: Kaufman, Howard L, et al.
Publicado: (2014)

Ipilimumab and radiation therapy for melanoma brain metastases
por: Silk, Ann W, et al.
Publicado: (2013)

Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)
por: Clark, Joseph I, et al.
Publicado: (2015)

A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study
por: Silk, Ann W., et al.
Publicado: (2022)

Two roads for oncolytic immunotherapy development
por: Kaufman, Howard L., et al.
Publicado: (2019)

Adjuvant Ipilimumab in High-Risk Uveal Melanoma
por: Fountain, Eric, et al.
Publicado: (2019)

Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
por: Koguchi, Yoshinobu, et al.
Publicado: (2021)

An Open–Label, Randomized, Multi–Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin–2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma
por: Hasanov, Merve, et al.
Publicado: (2021)

Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2
por: Clark, Joseph I, et al.
Publicado: (2021)

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial
por: Chesney, Jason A, et al.
Publicado: (2023)

High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014
por: Dutcher, Janice P, et al.
Publicado: (2014)

Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
por: Long, Georgina V., et al.
Publicado: (2021)

Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study
por: Curti, Brendan D, et al.
Publicado: (2022)

Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM(SM) registry
por: Fishman, M., et al.
Publicado: (2019)

Real world experience in low-dose ipilimumab in combination with PD-1 blockade in advanced melanoma patients
por: Kirchberger, Michael Constantin, et al.
Publicado: (2018)

Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report
por: Appelbaum, Jacob, et al.
Publicado: (2018)

Ipilimumab
Publicado: (2012)

Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade
por: Bommareddy, Praveen K., et al.
Publicado: (2019)

Treating Pediatric Myocarditis with High Dose Steroids and Immunoglobulin
por: Schauer, Jenna, et al.
Publicado: (2022)

Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms
por: Al-Toubah, T., et al.
Publicado: (2021)

An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients
por: Colston, Elizabeth, et al.
Publicado: (2018)

Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer
por: Somlo, G, et al.
Publicado: (2002)

Dose calculation accuracy of lung planning with a commercial IMRT treatment planning system
por: McDermott, Patrick N., et al.
Publicado: (2003)

Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer
por: Scholz, Mark, et al.
Publicado: (2017)

Complete Remission of Vocal Cord Cancer Treated With Low-Dose Ipilimumab Plus Nivolumab Combined With Interleukin-2 and Hyperthermia
por: Kleef, Ralf, et al.
Publicado: (2021)

Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin(® )(HD IL-2) and Ipilimumab Yervoy(® )) in patients with metastatic melanoma (proclivity 02)
por: Patel, Sapna, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_sajeh00em1cd3vsb7usmq0sg26